logo dark logo light logo
  • About Us
  • Our Science
  • Careers
  • News
Mobile Logo
  • About Us
  • Our Science
  • Careers
  • News
Sep 27
Kate Morreale
Mythic News, Press Releases

Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022

Waltham, Mass., September 27, 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based

0 Comments
Like
Aug 23
Kate Morreale
Mythic News, Press Releases

Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer

Waltham, Mass., August 23 2022 (BUSINESS WIRE) -- Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based

0 Comments
Like
Dec 14
Mythic Author
Mythic News, Press Releases

Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing

  Mythic’s FateControl™ technology holds the potential to dramatically improve the therapeutic index of ADCs, independent of the linker and payload Series

Like

Categories

  • Mythic News
  • Press Releases

Recent News

  • Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022 September 27, 2022
  • Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer August 23, 2022
  • Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing December 14, 2021
© Mythic Therapeutics. All rights reserved.  100 Beaver Street, Waltham, MA 02453 USA  Contact Us
Web Design: Someone Creative